Join Growin Stock Community!

Nektar therapeuticsNKTR.US Overview

US StockHealthcare
(No presentation for NKTR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NKTR AI Insights

NKTR Overall Performance

NKTR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NKTR Recent Performance

-0.45%

Nektar therapeutics

0.05%

Avg of Sector

-0.31%

S&P500

NKTR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NKTR Key Information

NKTR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NKTR Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Price of NKTR

NKTR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NKTR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
30.83
PB Ratio
21.72
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
87.26%
Net Margin
-192.87%
Revenue Growth (YoY)
-32.79%
Profit Growth (YoY)
-13.50%
3-Year Revenue Growth
-20.68%
3-Year Profit Growth
-14.18%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.94
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
30.83
PB Ratio
21.72
Price-to-FCF
-
Gross Margin
87.26%
Net Margin
-192.87%
Revenue Growth (YoY)
-32.79%
Profit Growth (YoY)
-13.50%
3-Year Revenue Growth
-20.68%
3-Year Profit Growth
-14.18%

  • When is NKTR's latest earnings report released?

    The most recent financial report for Nektar therapeutics (NKTR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NKTR's short-term business performance and financial health. For the latest updates on NKTR's earnings releases, visit this page regularly.

  • What is the operating profit of NKTR?

    According to the latest financial report, Nektar therapeutics (NKTR) reported an Operating Profit of -31.67M with an Operating Margin of -268.63% this period, representing a growth of 7.78% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is NKTR's revenue growth?

    In the latest financial report, Nektar therapeutics (NKTR) announced revenue of 11.79M, with a Year-Over-Year growth rate of -51.13%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does NKTR have?

    As of the end of the reporting period, Nektar therapeutics (NKTR) had total debt of 91.92M, with a debt ratio of 0.31. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NKTR have?

    At the end of the period, Nektar therapeutics (NKTR) held Total Cash and Cash Equivalents of 41.03M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NKTR go with three margins increasing?

    In the latest report, Nektar therapeutics (NKTR) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -268.63%%, and net margin of -301.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NKTR's profit trajectory and future growth potential.

  • Is NKTR's EPS continuing to grow?

    According to the past four quarterly reports, Nektar therapeutics (NKTR)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.87. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NKTR?

    Nektar therapeutics (NKTR)'s Free Cash Flow (FCF) for the period is -48.88M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 9.59% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NKTR?

    The latest valuation data shows Nektar therapeutics (NKTR) has a Price-To-Earnings (PE) ratio of -9.43 and a Price/Earnings-To-Growth (PEG) ratio of 0.21. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.